This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cramer Quick Take: Focus on ASCO

NEW YORK ( TheStreet) -- "Mad Money" Research Director Nicole Urken met with TheStreet's Jim Cramer to discuss some powerful cancer-fighting procedures that have begun to emerge.

With the American Society of Clinical Oncology conference wrapping up this week in Chicago, some old-name pharmaceutical stocks are getting a boost for their recent progress on cancer-fighting techniques.

Two names that Cramer and Urken continue to like are Merck (MRK - Get Report) and Bristol-Myers (BMY - Get Report).

The new PD-1 procedure, which involves using the patient's immune system to target and fight cancerous cells, hasn't seemed to gain much traction until now.

This technique is something that Gilead (GILD - Get Report) is looking at, even though the company has been focused on treating HIV and hepatitis C. BioMarin (BMRN - Get Report) is also looking at entering the space.

"These are all positive names with long-term drivers," Urken said, adding that they are "also helping improve people's lives and fight disease."

-- Written by Bret Kenwell in Petoskey, Mich.

Bret Kenwell currently writes, blogs and also contributes to Rocco Pendola's Weekly Options Newsletter. Focuses on short- to intermediate-term trading opportunities that can be exposed via options. He prefers to use debit trades on momentum setups and credit trades on support/resistance setups. He also focuses on building long-term wealth by searching for consistent, quality dividend paying companies and long-term growth companies. He considers himself the surfer, not the wave, in relation to the market and himself. He has no allegiance to either the bull side or the bear side.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
BMRN $120.28 -2.17%
BMY $65.80 -0.30%
GILD $103.70 -1.44%
MRK $57.60 0.16%
AAPL $130.28 0.47%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs